Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors

This study is comparing two types of vaginal laser treatment — fractional CO2 laser and erbium:YAG laser — for managing genitourinary syndrome of menopause (GSM), which causes vaginal dryness, pain, and urinary symptoms, in women with breast cancer who are taking aromatase inhibitors (hormone-blocking drugs). **You may be eligible if...** - You have a history of breast cancer and were premenopausal at diagnosis - You are currently taking an aromatase inhibitor as part of your ongoing breast cancer treatment - You are currently menopausal (whether from chemotherapy, surgery, or medication) - You have moderate to severe GSM symptoms (vaginal dryness, pain, or discomfort rated 4 or higher on a 10-point scale) **You may NOT be eligible if...** - You are unwilling to avoid vaginal intercourse for 1 week after each laser session - You used non-hormonal vaginal products in the last 6 weeks - You used hormone therapy (local or systemic) in the past 6 months - You have a genital infection, vaginal prolapse grade 2 or higher, or vaginal mesh - You are still actively undergoing radiation or chemotherapy - You have vaginal narrowing that prevents laser probe insertion Talk to your doctor to see if this trial is right for you.